2026 Half-year interim results

GlaxoSmithKline Capital PLC

29 July 2026

 

Issued: 29 July 2026, London UK

GlaxoSmithKline Capital plc publication of Interim Management Report 2026

 

GlaxoSmithKline Capital plc (the "Company") today announced the publication on the GSK Group ("GSK") website, www.gsk.com*, of its Interim Management Report in respect of the half year ended 30 June 2026.

In compliance with the UK Financial Conduct Authority's ("FCA") UK Listing Rules sourcebook rule 9.6.1, a copy of the Company's 2026 Interim Management Report has been submitted to the FCA's National Storage Mechanism ("NSM") submission portal via the Electronic Submission System.

The Company is applying the exemption available to it under the FCA's Disclosure Guidance and Transparency Rules sourcebook rule 6.3.5(1A) and has made the regulated information available in unedited full text on the NSM, rather than setting out the full text of the regulated information within this announcement.

A copy of the Company's Interim Management Report in respect of the half year ended 30 June 2026, which includes a description of the principal risks and uncertainties affecting it, together with a Directors' responsibility statement, can be viewed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

V A Whyte
Company Secretary
29 July 2026

* https://www.gsk.com/en-gb/company/codes-standards-and-reports/#gsk-capital-plc-annual-reports

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q2 Results for 2026.

Registered in England & Wales:

No. 02258699

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

END